Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 USD | -0.63% | +0.63% | -17.45% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 273.6 | 221 | 222.4 | 190.5 | - | - |
Enterprise Value (EV) 1 | 79.34 | 90.9 | -53.8 | 69.59 | -67.11 | 153.7 |
P/E ratio | -1.35 x | -5.09 x | -3.56 x | -2.6 x | -2 x | -1.69 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -4.05 x | -2.01 x | 0.88 x | -0.93 x | 0.74 x | -1.3 x |
EV / FCF | -4.41 x | -2.57 x | 1.25 x | -0.8 x | 0.74 x | -1.36 x |
FCF Yield | -22.7% | -38.9% | 80.1% | -125% | 136% | -73.4% |
Price to Book | 1.22 x | 1.17 x | 0.7 x | 0.99 x | 0.95 x | 2.06 x |
Nbr of stocks (in thousands) | 40,470 | 40,925 | 57,910 | 60,080 | - | - |
Reference price 2 | 6.760 | 5.400 | 3.840 | 3.170 | 3.170 | 3.170 |
Announcement Date | 3/28/22 | 3/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -19.58 | -45.2 | -61.08 | -74.96 | -90.45 | -117.8 |
EBIT 1 | - | -19.58 | -45.24 | -61.14 | -77.92 | -97.28 | -117.5 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -100.6 | -42.86 | -52.37 | -77.79 | -119.3 | -145.4 |
Net income 1 | -7.325 | -100.6 | -42.86 | -52.37 | -68.63 | -93.45 | -116.6 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -11.73 | -5.020 | -1.060 | -1.080 | -1.221 | -1.581 | -1.871 |
Free Cash Flow 1 | - | -18 | -35.31 | -43.08 | -87 | -91.21 | -112.8 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 4/12/21 | 3/28/22 | 3/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | - | - | - | - | -18.47 | -16.08 | -17.02 | -19.93 | -21.96 | - |
EBIT 1 | -3.935 | -8.415 | -9.206 | -10.41 | -11.37 | -14.25 | -13.14 | -13.48 | -16.04 | -18.49 | -16.68 | -17.3 | -19.24 | -20.6 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.902 | -8.349 | - | -10.15 | -10.71 | -12.87 | -11.31 | -11.61 | -12.96 | -16.5 | -10.34 | -11.12 | -12.44 | -13.9 | - |
Net income 1 | -3.902 | -8.349 | - | -10.15 | -10.71 | -12.87 | -11.31 | -11.61 | -12.96 | -16.5 | -15.53 | -16.58 | -17.89 | -18.63 | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1000 | 1.980 | -0.2300 | -0.2500 | -0.2600 | -0.3200 | -0.2800 | -0.2800 | -0.2400 | -0.2900 | -0.2725 | -0.2880 | -0.3177 | -0.3400 | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/28/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/27/23 | 5/9/23 | 8/8/23 | 11/13/23 | 3/26/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 194 | 130 | 276 | 121 | 258 | 36.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -18 | -35.3 | -43.1 | -87 | -91.2 | -113 |
ROE (net income / shareholders' equity) | - | -76.4% | -20.7% | -23% | -27.5% | -44.5% | -72.8% |
ROA (Net income/ Total Assets) | - | - | - | -20.7% | - | - | - |
Assets 1 | - | - | - | 253.4 | - | - | - |
Book Value Per Share 2 | - | 5.560 | 4.600 | 5.490 | 3.210 | 3.350 | 1.540 |
Cash Flow per Share 2 | - | -0.9000 | -0.8700 | -0.8900 | -0.8300 | -1.000 | - |
Capex 1 | - | 0.04 | 0.16 | 0.02 | 0.04 | 0.18 | 0.04 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/12/21 | 3/28/22 | 3/27/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.45% | 190M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABOS Stock
- Financials Acumen Pharmaceuticals, Inc.